Patents by Inventor Chuantao ZHA

Chuantao ZHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230312564
    Abstract: Provided are an aromatic ring-lactam compound as shown in formula (I), and a preparation method therefor and the use thereof. The aromatic ring-lactam compound has a novel structure, has good inhibitory activity on ERK1/2 kinases, can inhibit the proliferation of tumor cells, and has anti-tumor activity.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 5, 2023
    Inventors: Huixin WAN, Chuantao ZHA, Jingui MA, Jingkang SHEN
  • BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE
    Publication number: 20230174526
    Abstract: A benzothiazolyl biaryl compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorph, or a prodrug thereof, a preparation method therefor, and a use thereof as a KRASG12C inhibitor.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 8, 2023
    Inventors: Huixin WAN, Chuantao ZHA, Jingui MA, Jingkang SHEN
  • Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
    Patent number: 10562900
    Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Meiyu Geng, Lei Liu, Lei Jiang, Min Huang, Chuantao Zha, Jing Ai, Lei Wang, Jianhua Cao, Jian Ding
  • INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF
    Publication number: 20170275291
    Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
    Type: Application
    Filed: August 19, 2015
    Publication date: September 28, 2017
    Applicants: Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Meiyu GENG, Lei LIU, Lei JIANG, Min HUANG, Chuantao ZHA, Jing AI, Lei WANG, Jianhua CAO, Jian DING